Navigation Links
New Drug Application Submitted for Investigational Antibiotic Doripenem

RARITAN, N.J., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.

According to the Centers for Disease Control and Prevention (CDC), two million Americans develop hospital-acquired infections each year, and approximately 90,000 die as a result. Approximately 70 percent of these infections are resistant to at least one antibiotic. Pneumonia is the second, most-common, hospital-acquired infection in the United States and is associated with substantial morbidity and mortality.

Doripenem belongs to a class of antibacterial agents called carbapenems, which are useful in treating life-threatening infections caused by Gram-negative(1) and Gram-positive(2) bacteria. The data supporting the NDA showed doripenem was an effective treatment for hospital-acquired pneumonia. The data also demonstrated the effectiveness of doripenem against infections caused by Gram-negative bacteria, such as Pseudomonas aeruginosa and Enterobacteriaceae, including strains of these bacteria that are resistant to other therapies.

Pseudomonas aeruginosa is one of the leading causes of hospital-acquired infections and, because of increasing multi-drug resistance, treatment options are limited. In general, there are few antibiotics available or currently in development to treat the resistant infections - which can be potentially life-threatening - associated with these Gram-negative bacteria.

In clinical trials, doripenem was well-tolerated. The most common treatment-emergent adverse events seen were diarrhea, nausea, constipation, urinary tract infection and decubitus ulcer, commonly known as a bedsore.


'"/>




Page: 1

Related medicine news :

1. Prostate Cancer Can Be Treated By Application Of LASER Technology
2. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
3. Venus Remedies Files 5th International Patent Application
4. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
5. Recd Number of Abstracts Submitted for Sci Cong on Osteoporosis
6. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
7. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
8. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
9. Antibiotics Helps Autism
10. Antibiotics losing their power against acne
11. Antibiotic induces liver damage in children with E.COLI infections.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... Beverly Hills, California (PRWEB) , ... February 17, ... ... 273-3007, info@drvallecillos.com , drvallecillos.com , Beverly Hills plastic surgeon ... reduce subcutaneous fat cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been ...
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for ... so many other applications. Users can pick and choose from hand-crafted trend-setting ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a ... Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed ... roof. Smiles by Seese serves patients of all ages with excellence in general, restorative, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... sustainable systems change designed to further positively impact the health and wellness of ... has long considered it our duty to seriously consider releasing our assets beyond ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)...  Perrigo Company plc (NYSE, TASE: PRGO) today announced it ... Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg ... cough in adults and children 6 years of age and ... were approximately $16 million.   ...
(Date:2/17/2017)...  In partnership with CitiHope , Panexus ... The Jack Brewer Foundation (JBF Worldwide) has ... worth of medicine to Innovating Health International ... non-profit dedicated to treating chronic diseases and addressing women,s health ... Haiti and providing these medicines to ...
(Date:2/17/2017)... 2017 On Thursday, February 16, ... lower at the closing bell, while the Dow Jones ... benchmark. Moreover, five out of nine sectors ended Thursday,s ... market sentiment, Stock-Callers.com assessed the following Medical Appliances & ... SNN ), ABIOMED Inc. (NASDAQ: ...
Breaking Medicine Technology: